753421-85-1

Basic information

• Product Name: LCZ Impurity
• Synonyms: Sacubitril Impurity 8;Sacubitril Impurity 9;Sacubitril Impurity 10;LCZ696(Sacubitril/Valsartan) IMP;LCZ Impurity;Sacubitril Impurity 11;Sacubitril Impurity 12;Sacubitril Impurity 13
• CAS NO: 753421-85-1
• Molecular Formula: C20H25NO2
• Molecular Weight: 311.42
• EINECS: -0
• Mol File: 753421-85-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 459.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.057±0.06 g/cm3(Predicted)
• PKA: 9.58±0.42(Predicted)
• CAS DataBase Reference: LCZ Impurity(CAS DataBase Reference)
• NIST Chemistry Reference: LCZ Impurity(753421-85-1)
• EPA Substance Registry System: LCZ Impurity(753421-85-1)

Safety Data

• Hazardous Substances Data: 753421-85-1(Hazardous Substances Data)

Usage

General Description

LCZ Impurity refers to a group of chemical impurities that may be associated with the manufacturing process or degradation of LCZ, a drug used to treat high blood pressure and heart failure. These impurities may include related substances, degradation products, or other contaminants that can affect the purity and quality of the final product. It is important to monitor and control the levels of LCZ Impurities to ensure the safety and effectiveness of the drug for patients. Quality control measures and analytical methods are typically employed to detect and limit the presence of LCZ Impurities in pharmaceutical products.

Upstream product

• 4676-51-1 (2R)-diethyl 2-methylsuccinate 
• 1012341-48-8 (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid 
• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 64-17-5 ethanol 
• 149709-56-8 methyl N-(tert-butoxycarbonyl)-O-[(trifluoromethyl)sulfonyl]-D-tyrosinate 
• 76757-90-9 N-(tert-butoxycarbonyl)-D-tyrosine methyl ester 
• 149709-60-4 ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoate 
• 149709-59-1 (R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid ethyl ester 
• 149709-58-0 (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanal 
• 162972-36-3 (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino>-N-methoxy-N-metyl<1,1'-biphenyl>-4-propanamide 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 

Relevant articles and documents

Preparation method and application of sacubitril intermediate

The invention discloses a preparation method and application of a sacubitril intermediate. The sacubitril intermediate disclosed by the invention is obtained by taking itaconic anhydride as a raw material, performing chiral reduction, esterification, selective hydrolysis and carboxyl activation, and finally conducting coupling with 4-biphenylacetic acid. The invention also provides a method for preparing sacubitril by using the sacubitril intermediate. The preparation method provided by the invention has the advantages of easily available raw materials, simple process, economy, environmental protection and the like, and is more suitable for industrial production compared with other routes.

SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF

The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril. The method disclosed herein has advantages of easily obtained raw materials, simple preparation process, low cost, environment friendly, and etc., which is very suitable for industrial production.

A LCZ696 preparation method of drug impurity (by machine translation)

The present invention provides a LCZ696 preparation method of drug impurities, including: the (2 R, 4 S) - 5 - (biphenyl - 4 - yl) - 4 - [(uncle butoxy carbonyl) amino] - 2 - methyl valeric acid in chloro- medicinal preparation in the reaction with the organic alcohol, in order to get the product and succinic anhydride as a raw material, preparation (2 R, 4 S) - 5 - biphenyl - 4 - yl - 4 - (2, 5 - dicarbonyl - pyrrolidine - 1 - yl) - 2 - methyl pentanoate; make (2 R, 4 S) - 5 - biphenyl - 4 - yl - 4 - (2, 5 - dicarbonyl - pyrrolidine - 1 - yl) - 2 - methyl pentanoate hydrolyzed under acidic conditions, make (2 R, 4 S) - 5 - biphenyl - 4 - yl - 4 - (2, 5 - dicarbonyl - pyrrolidine - 1 - yl) - 2 - methyl valeric acid. The method of the invention the operation is simple, low cost, and is capable of LCZ696 pharmaceutical quality control to provide qualified reference substance. (by machine translation)